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Abstract
Background: Evidence from diverse areas of medicine (e.g., cardiovascular disease, diabetes) indicates that
healthcare providers (HCPs) often do not adhere to clinical practice guidelines (CPGs) despite a clear indication to
implement recommendations—a phenomenon commonly termed clinical inertia. There are a variety of reasons
for clinical inertia, but HCP-related factors (e.g., knowledge, motivation, agreement with guidelines) are the most
salient and amenable to intervention aimed to improve adherence. CPGs have been developed to support the
safe and effective prescription of opioid medication for the management of chronic non-cancer pain. The extent
of physician uptake and adherence to such guidelines is not yet well understood. The purpose of this review is to
synthesize the published evidence about knowledge, attitudes, beliefs, and practices that HCPs hold regarding
the prescription of opioids for chronic non-cancer pain.
Methods: An experienced information specialist will perform searches of CINAHL, Embase, MEDLINE, and PsycINFO
bibliographic databases. The Cochrane library, PROSPERO, and the Joanna Briggs Institute will be searched for
systematic reviews. Searches will be performed from inception to the present. Quantitative and qualitative
study designs that report on HCP knowledge, attitudes, beliefs, or practices in North America will be eligible
for inclusion. Studies reporting on interventions to improve HCP adherence to opioid prescribing CPGs will
also be eligible for inclusion. Two trained graduate-level research assistants will independently screen articles
for inclusion, perform data extraction, and perform risk of bias and quality assessment using recommended
tools. Confidence in qualitative evidence will be evaluated using the Grades of Recommendation, Assessment,
Development, and Evaluation-Confidence in the Evidence from Qualitative Reviews (GRADE-CERQual) approach.
Confidence in quantitative evidence will be assessed using the GRADE approach.
Discussion: The ultimate goal of this work is to support interventions aiming to optimize opioid prescribing
practices in order to prevent opioid-related morbidity and mortality without restricting a HCP’s ability to select the
most appropriate treatment for an individual patient.
Systematic review registration: PROSPERO CRD42018091640.
Keywords: Clinical inertia, Clinical practice guideline adherence, Opioids, Chronic pain, Systematic review
* Correspondence: jarash@mun.ca
1Department of Psychology, Memorial University of Newfoundland, 230
Elizabeth Ave, St. John’s, NL A1B 3X9, Canada
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rash et al. Systematic Reviews           (2018) 7:189 
https://doi.org/10.1186/s13643-018-0858-7
Background
The prescription of opioid analgesics represents a double-
edged sword. On the one hand, opioid analgesics (e.g.,
morphine, oxycodone, fentanyl) have been shown to pro-
vide modest improvement in pain and function for pa-
tients with chronic non-cancer pain. On the other hand,
prescription opioids may lead to opioid-induced algesia [1,
2], addiction, or diversion, particularly at high doses (e.g.,
≥ 200 mg morphine equivalents/day) [3]. As such, pre-
scription opioids are associated with serious and increas-
ing public health problems, such as addiction treatment
admissions and overdose death [4].
Opioid prescribing within the context of chronic pain
management
In 2011, the United States Institute of Medicine concluded
that chronic pain, defined as pain that persists longer than
3 months, or beyond the expected duration of healing [5],
is a public health concern and should be treated as a dis-
ease itself [6]. While estimates vary depending on survey
methodology, nationally representative data from Canada,
the USA, Germany, and other European countries indi-
cates that 20 to 30% of adults (≥ 18 years of age) suffer
with chronic non-cancer pain [7–11]. The prevalence of
chronic pain is higher among women [12] and ethnic mi-
norities [13] and increases with age. Approximately 65%
of community-dwelling seniors and 80% of older adults
living in care facilities experience chronic pain, including
cancer-related pain [14].
The goal of pain management is to decrease pain and
improve function while monitoring for adverse effects
[15]. In the late 1980s and early 1990s, the under-treat-
ment of pain, including among patients with chronic
non-cancer pain, garnered national attention in both the
USA and Canada. A classic 1986 publication describing
the treatment of chronic pain in 38 patients concluded
that opioid pain relievers could be prescribed safely on a
long-term basis [16]. Further, a letter to the editor of the
New England Journal of Medicine asserted that the rate
of addiction in patients receiving opioids was low [17].
This letter was heavily and uncritically cited as evidence
that addiction was rare with long-term opioid therapy,
many citing rates ≤ 1% [18]. Despite low-quality evi-
dence, these sources were widely cited to support the ex-
panded use of opioid medication for the management of
chronic pain [4]. By the late 1990s, healthcare pro-
viders (HCPs) were encouraged by pharmaceutical
companies and medical boards to be more proactive
in treating all types of pain (e.g., acute, palliative,
chronic) to alleviate suffering, including the prescrip-
tion of opioid analgesics at relatively high doses for
long durations [19]. The potential adverse effects of
long-term opioid use were under-appreciated and often
based on beliefs that opioids were safe for extended use
in patients with chronic pain with no known dosing
threshold. Opioid prescribing increased in a marked linear
fashion until 2013 when it began to plateau in the USA
[20] and Canada [21].
Trends in opioid prescribing morbidity and mortality
The past two decades have been characterized by a lin-
ear increase in the prescription of opioid medications. A
twofold increase in the consumption of hydrocodone
and fivefold increase in the use of oxycodone was ob-
served in the USA between 1999 and 2011 [22]. Obser-
vational data show a mean increase from 180 mg
morphine equivalents per person in the US population
per year in 1997 to 710 mg per person per year in 2010
[23]. This corresponded with a fourfold increase in the
sale of prescription opioids [23], a fivefold increase in
drug treatment admissions for prescription opioids
(from ~ 20,000 to ~ 120,000) [24], more than a twofold
increase in emergency department visits related to
pharmaceutical opioids [25], and a fourfold increase in
opioid-related overdose [26]. Although there is an un-
deniable rise in the availability of illicit opioids [27, 28],
it has also been argued that opioid-related mortality is
directly associated with the increase in opioid prescrip-
tions observed in Canada, the USA, Europe, the UK,
Spain, France, and Australia [21, 29–31]. Beyond the dir-
ect association, prescriber adjustment and tapering of
opioid analgesics have been associated with risk of non-
medical use, morbidity, and mortality as individuals turn
to illicit opioids in an attempt to manage their pain [32].
A systematic review of data from the USA and Canada
identified three interacting factors associated with
opioid-related mortality: (1) prescriber behaviors, (2) pa-
tient characteristics, and (3) systemic determinants [33].
Pertinent for this protocol, four ways that prescriber be-
haviors influence opioid-related mortality were eluci-
dated. First, results from seven studies indicated that
prescribing higher doses of opioids is associated with
opioid-related mortality. Second, seven studies reported
an association between more potent opioids, such as
fentanyl, and opioid-related mortality. Third, 14 studies
reported that the co-prescription of opioids with seda-
tives or more than one opioid was associated with the
observed increase in opioid-related mortality. This was
particularly relevant with the co-prescription of metha-
done which has a small window between therapeutic
and fatal doses. Finally, eight studies reported that an in-
crease in the number of opioid prescriptions played a
role in opioid mortality through increased availability.
The top quintile of prescribers was observed to issue
opioid prescriptions 4.5 times more frequently than the
next quintile and wrote the final prescription in 63% of
opioid-related deaths [34].
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Clinical practice guidelines for the prescription of opioid
medication
Clinical practice guidelines (CPGs) have been developed
by several countries, including the USA [35] and Canada
[2], to support evidence-based prescription of opioid
medication for the management of chronic non-cancer
pain. A systematic review of opioid prescribing CPGs
identified 13 guidelines reporting on recommendations
for the prescription of opioids for chronic pain between
2007 and 2013 [36]. While there is between-guideline
variability, clinical practice guidelines consistently rec-
ommend that HCPs (1) avoid doses ≥ 90–200 mg per
day, (2) acquire additional training prior to prescribing
methadone, (3) recognize risk of fentanyl patches, (4) ti-
trate cautiously, and (5) reduce doses by at least 25 to
50% when switching opioid [36]. Based on expert con-
sensus rather than rigorous supporting evidence, CPGs
also regularly support the use of risk assessment tools,
written treatment agreements, and urine drug tests to
mitigate risks.
Clinical inertia in the context of prescribing opioids for
chronic pain management
Despite their widespread availability and strong evidence
supporting the benefits of their use [37–39], there is a
long history of poor uptake of CPGs for chronic disease
management by HCPs, with many studies reporting rates
of non-adherence at or exceeding 50% [40–42]. HCP
non-adherence to CPGs is increasingly referred to as
“clinical inertia” [43]. Practically speaking, clinical inertia
refers to a HCP’s decision not to initiate, intensify, ti-
trate, or stop treatment despite an indication and recog-
nition of the need to do so. Clinical inertia has most
commonly been studied within the context of managing
chronic diseases, such as diabetes, cardiovascular dis-
ease, hypertension, and dyslipidemia. Within this area, it
has been estimated that clinical inertia is responsible for
up to 80% of myocardial infarctions and strokes within
the context of sub-optimally treated hypertension, dia-
betes, and dyslipidemia [44].
Our team recently published a review of clinical inertia
in the context of chronic disease management where we
elucidated the factors associated with this behavior [45].
In brief, clinical inertia is influenced by HCP factors (e.g.,
knowledge, agreement with guidelines, cognitive biases,
motivation), patient factors (e.g., sociodemographics, med-
ical history, lifestyle factors, treatment adherence), and
system factors (e.g., time constraints, resources, setting)
[45]. System- and patient-level interventions are often
mistakenly perceived as being more important or resulting
in greater benefit than HCP-level interventions. This
protocol will focus on HCP-related factors given that HCP
influences (1) account for 50% of variability in clinical in-
ertia [44], (2) are less well understood than system- and
patient-factors, (3) often require more sophisticated
behavioral corrective interventions, (4) are particularly
relevant given the difficult balance between under-pre-
scribing within the context of pain management and
over-prescribing within the context of aberrant use, and
(5) partially address a priority identified by patients and
clinicians who have taken part in a national chronic
pain research priority setting process [46].
It is difficult to estimate the impact of clinical inertia
on pain, opioid-related morbidity, and mortality because
of the relative paucity of available data. Consistent with
other chronic diseases, the available evidence suggests
that HCP adherence to opioid prescribing guidelines is
less than optimal [47]. For example, a survey of more
than 200 physicians in Wisconsin reported that only
38% were aware of at least one clinical practice guideline
for prescribing opioids in the management of chronic
pain [48]. Similarly, an assessment of HCP behavior in a
sample of 1300 physicians and residents in Massachu-
setts reported only partial compliance with national opi-
oid prescribing guidelines (e.g., 43% had a controlled
substance agreement, 34% provided > 2 early refills, 63%
utilized urine drug tests) [49].
There are many reasons why HCPs deviate from
CPGs. One obvious reason is insufficient knowledge.
Many HCPs are unaware that evidence of long-term ef-
fectiveness for opioids is lacking [4] or that risks include
hyperalgesia [50], androgen deficiency [51], and serious
fractures from falls [52]. A study of more than 700
family physicians in Canada reported that only 40% of
physicians correctly answered two of nine questions per-
taining to knowledge of opioid prescribing [53]. Inad-
equate training and a consequent lack of self-efficacy
(i.e., a belief in one’s own ability to personally affect
change) are other reasons. More than 70% of 636 family
physicians in the province of Quebec surveyed did not
feel confident that they could properly prescribe opioids
for chronic non-cancer pain, despite 75% of the sample
having received continuing education on the topic
within the previous year [54]. A similar study observed
that 54% of primary care providers surveyed in Massa-
chusetts did not feel sufficiently trained to prescribe opi-
oids [55]. Large volume and inaccessibility of guidelines
also contribute to HCP deviation from CPGs. A qualita-
tive study of 12 pain physicians in Ontario identified ex-
cessive length and poor formatting as a deterrent to the
implementation of the 2010 CPGs for the safe and ef-
fective use of opioids for chronic non-cancer pain [56].
An additional reason is fear; nearly 50% of 226 physi-
cians surveyed in Wisconsin reported altering opioid
prescribing practices (e.g., limiting refills, lowering dose,
reducing prescribed quantity) due to fear of investigation
by regulatory agencies [48]. This is also problematic as it
may lead to under-treatment of pain or use of an
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inappropriate opioid tapering schedule contributing to
unnecessary suffering, such as aggressive tapering.
In summary, it is safe to assume that adherence to the
current guidelines for the prescription of opioid medica-
tion for the management of chronic non-cancer pain will
make no exception to the general observation that ad-
herence to recommendations detailed in CPG is subopti-
mal, and would therefore benefit from interventions to
improve adherence.
Objective of the proposed systematic review
To date, there has been no literature synthesis pertaining
to factors associated with HCP clinical inertia in the
context of prescribing opioid medication for chronic
non-cancer pain. A systematic review of this nature is
needed for at least four reasons:
1. To elucidate the factors associated with prescribing
opioid analgesics in accordance with CPGs.
2. To explore the relative effectiveness of interventions
intended to improve the uptake of CPG
recommendations for the prescription of opioids
to manage chronic non-cancer pain.
3. To guide the development of novel interventions to
optimizing the prescription of opioid analgesics.
4. To identify gaps in knowledge pertaining to clinical
inertia for the prescription of opioid analgesics.
Methods
Protocol reporting and registration
This review protocol was prepared in accordance with
the Preferred Reporting Items for Systematic Review and
Meta-Analyses Protocol (PRISMA-P) guidelines [57]
(refer to Additional file 1). The protocol is registered
with Prospective Register of Systematic Reviews (PROS-
PERO; registration#CRD42018091640).
Structured clinical question(s)
1. What are the knowledge, attitudes, beliefs, and
practices that HCPs hold regarding the prescription
of opioids for chronic non-cancer pain?
2. Do knowledge, attitudes, beliefs, and practices
pertaining to prescribing opioids for the
management of chronic non-cancer pain differ by
HCP characteristics (e.g., sex, discipline, duration
of practice) or patient factors (e.g., sex, history of
addiction)?
3. What is the prevalence of clinical inertia for
prescribing opioids for the management of chronic
non-cancer pain?
4. Have interventions been developed that have an
impact on opioid prescribing behavior for the
management of chronic non-cancer pain?
Data sources and search strategy
A preliminary search strategy will be created under the
guidance of an experienced information specialist (BS;
refer to Additional file 2). A second information special-
ist will peer-review the strategy prior to execution using
the Peer Review for Electronic Search Strategies (PRESS)
checklist [58]. Using the OVID platform, we will search
Ovid MEDLINE® (1946 to April 23, 2018), including
Epub Ahead of Print and In-Process & Other Non-
Indexed Citations, Embase Classic + Embase (1947 to
April 23, 2018), and PsycINFO (1806 to April 23, 2018).
We will also search the Cochrane Library on Wiley and
CINAHL (1981 to present) on Ebsco. The Joanna Briggs
Institute EBP Database and PROSPERO (2011 to
present) will be searched for completed systematic
reviews.
Search strategies will incorporate controlled vocabu-
lary for relevant themes (e.g., “Analgesics,” “Opioid,”
“Health Personnel,” “Guideline Adherence”) and key-
words (e.g., “opioid,” “physician,” “clinical inertia”). Vo-
cabulary and syntax will be adjusted across databases.
No language restriction will be imposed, but where pos-
sible, animal-only studies will be removed from the re-
sults. No study-specific filters will be applied given the
wide range of study designs of interest.
Study eligibility criteria
Population
Our population of interest is HCPs who prescribe opioid
medication (e.g., physician, dentist, nurse practitioner).
Studies that include medical residents will also be eli-
gible for inclusion.
Interest
Clinical inertia (i.e., barriers and facilitators of adherence
to long-term opioid prescribing guidelines) for the man-
agement of chronic non-cancer pain. We also aim to
capture interventions that have been conducted to im-
prove adherence to opioid prescribing guidelines within
the context of chronic pain.
Context
Primary and specialist care of patients with chronic
non-cancer pain in North America.
Outcomes
HCP knowledge, attitudes, beliefs, and practices pertain-
ing to opioid prescribing guidelines for the management
of chronic non-cancer pain. HCP behavior will be coded
for clinical inertia.
Designs
A range of study designs will be eligible. Survey and
epidemiological, qualitative, and uncontrolled studies
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reporting on facilitators and barriers towards imple-
menting long-term opioid prescribing guidelines will
be eligible given that such research can maximize the
value of a systematic review to inform clinical prac-
tice, policy, and decision-making [59, 60]. Controlled
studies, experimental designs, non-randomized con-
trolled studies, and retrospective and prospective co-
hort studies that include a control group, including
before-after studies, will be eligible for inclusion in
order to evaluate the efficacy/effectiveness of inter-
ventions designed to improve adherence to long-term
opioid prescribing guidelines.
The following inclusion criteria will be applied:
 Study involves the prescription of opioid medication
for adults (≥ 18 years of age). We chose to focus on
adults given that comparable guidelines have not
been published for children and youth [61]. As such,
practice and clinical inertia would likely be quite
different for children/youth compared to adults.
 The study concerned at least one of the following:
knowledge, attitudes, beliefs, or practices pertaining
to long-term opioid prescribing for the management
of chronic non-cancer pain.
 The study reported data from HCPs who prescribes
opioid medication (e.g., physician, specialist (MD),
dentist, pharmacist, nurse practitioner). Studies that
include medical residents are also considered eligible
for inclusion.
 The study reports on original data. Multiple reports
of single studies will be handled avoiding duplication
of source data.
 The study was conducted in North America. We
chose this distinction because opioid-related
prescribing practices, non-medical use, and harms
are greater in North America than anywhere else
in the world [62]. Differences in the organization
of health systems, prescription practices, dispensing
and medical cultures, and patient expectations have
been proposed as factors that contribute to the
differences observed [62].
The following exclusion criteria will be applied:
 The primary focus of the study pertains to non-
medical opioid use (i.e., opioid abuse and
dependence).
 The primary focus of the study pertains to the
prescription of medication to prevent or manage
non-medical opioid use (e.g., naloxone, suboxone,
methadone). Studies focusing on the prescription
of these medications will be eligible if they are
prescribed specifically for pain management.
 Conference abstracts.
Screening and data extraction
Two trained graduate-level research assistants will inde-
pendently screen titles and abstracts of all identified
search results for potential inclusion. The reviewers will
select all potentially relevant citations reporting on HCP
knowledge, attitudes, beliefs, or practices regarding pre-
scribing opioid medication for chronic non-cancer pain.
In doubt, references will be included at the title and
abstract level. Full-text publications of all potentially
relevant articles, selected by either reviewer, will be re-
trieved and examined for eligibility. The reference man-
agement software Rayyan [63] will be used to remove
duplicates and sort inclusions and exclusions. Agree-
ment between reviewers will be quantified using the
Kappa statistic [64] before proceeding to solve disagree-
ments. Disagreements on inclusion and exclusion of arti-
cles between reviewers will be resolved by consensus or
arbitration by a third reviewer (JAR) if necessary. The
study selection process will be documented using a
PRISMA flow diagram [65].
In duplicate, the same two reviewers will independ-
ently extract information from all potentially eligible
studies using a pre-designed data extraction Excel
spreadsheet. Interpreters will be enlisted to screen and
translate non-English language studies as required. Two
levels of extraction will occur. Limited extraction will be
implemented for all articles that were identified as po-
tentially eligible after the initial screening of titles and
abstracts for inclusion and exclusion criteria and will in-
clude the following:
1. Journal article information (i.e., first author, journal,
publication year).
2. Basic screening of inclusion and exclusion
criteria as outlined in the “Study eligibility
criteria” section.
The reviewers will then categorize the articles as “in”
or “out” and list the reason for exclusion. Excluded arti-
cles will be listed in the PRISMA diagram, grouped by
reasons for exclusion.
Following the brief extraction, full-data extraction of
included articles will be completed independently by
each reviewer. The following information will be ex-
tracted for each article:
1. Information on methodology (i.e., study design,
length of follow-up, country, incentives offered)
2. Participant information (i.e., total sample size,
recruitment method, defined sub-groups, provider
discipline)
3. Details on the measures used (i.e., instruments
used, intervention characteristics, method of
delivery)
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4. Outcomes: Similar to other systematic reviews of
physician beliefs [66], knowledge, attitudes, beliefs,
and practice will be extracted verbatim and coded
in accordance with the 14 domains defined by the
Theoretical Domains Framework [67, 68]. Inter-
rater reliability of these categories will be assessed
using the Kappa statistic [64].
5. Results of the study (e.g., response rate, missing
data, handling of missing data, sub-groupings,
proportion of HCPs endorsing beliefs along with
range and confidence intervals).
6. Risk of bias. Risk of bias will be collected using
validated tools, refer to the “Risk of bias and quality
assessment” section.
Once completed, the full extractions will be compared
across raters to ensure accuracy. Discrepancies will be
resolved by an independent arbiter (JAR).
Risk of bias and quality assessment
The methodological quality and risk of bias of included
studies will be assessed independently and in duplicate
by the same two trained research assistants. Risk of bias
in randomized trials will be assessed using a modified
version [69] of the Cochrane risk of bias tool [70]. The
domains assessed include random sequence generation,
allocation concealment, blinding of participants and
personnel, attrition, reporting bias, and other sources of
bias. Each domain will be assigned a judgment of “high
risk of bias” or “low risk of bias” [70]. Corresponding au-
thors of studies assessed will be contacted for clarifica-
tion when insufficient evidence is reported to assess risk
of bias. No study-level summary judgment of risk of bias
will be performed given that such summative judgments
do not correspond with treatment outcomes [71].
Methodological quality of cross-sectional studies will
be assessed using the “instrument for risk of bias in
cross-sectional studies of attitudes and practices” avail-
able from Evidence Partners and contributed by the
Clinical Advances Through Research and Information
Translation (CLARITY) Group at McMaster University
[72]. Five domains are assessed for cross-sectional sur-
vey studies, including representativeness of sample to
the population of interest, adequacy of response rate,
missing data, clinical sensibility, and reliability and valid-
ity of the instrument used. Each domain is assigned a
judgment of “definite risk of bias,” “probable risk of
bias,” “probable risk of low bias,” or “definite risk of low
bias.” A table will be constructed that depicts risk of
bias.
Methodological quality of cohort studies will be
assessed using Joanna Briggs Institute checklist for co-
hort studies [73]. Eleven domains are assessed, includ-
ing similarity of groups recruited, timing of exposure,
validity and reliability of exposure, identification of
confounding factors, mitigation of confounds, validity
and reliability of outcome measured, adequacy of
follow-up, completeness of follow-up, appropriateness
of statistical analyses. Each domain is assigned a rating
of “yes,” “no,” “unclear,” or “not applicable.” A table will
be constructed that depicts risk of bias.
Confidence in information obtained from qualitative
studies will be assessed in accordance with recommenda-
tions made by the Cochrane Qualitative and Implementa-
tion Methods Group [74] using a multi-dimensional
concept of quality that includes (1) clarity of aims and re-
search question, (2) congruence between questions and
methods, (3) rigor of sampling and data collection, and (4)
overall conceptual depth and breadth are reflected in
study design, process, and results. As recommended [74],
information will be collected by having two independent
raters appraise study quality using the 10-item Critical
Appraisal Skills Programme (CASP; [75]) quality assess-
ment tool for qualitative studies. Each item will be rated
as “yes,” “no,” or “unclear.” Quality assessment will be
depicted using a table.
Approach to evidence synthesis
Included studies will be categorized according to study
design. Frequencies and percentages will be reported for
categorical variables. Means and standard deviations
(SDs) or median and interquartile range will be reported
for continuous data as appropriate. The extracted pro-
portions of studies that include the same category of
knowledge, beliefs, attitudes, and practices will be
pooled. A Q-test adapted for proportions will be used to
test for heterogeneity of proportions [64]. As recom-
mended [64], random effects models will be performed
to account for the imperfect measurement of knowledge,
beliefs, attitudes, and practices. The proportions from
each study will be weighted by the size of the respective
sample. If a single study uses several items to measure
the same underlying construct (e.g., “prescribing guide-
lines are developed using populations that are not repre-
sentative of the chronic pain presentations that I see in
my practice”), then the most commonly used item will
be utilized. Results will be presented as pooled propor-
tions, 95% confidence intervals, range, and pooled fre-
quencies for each category of knowledge, attitudes,
beliefs, and practices. If sufficient data is obtained, re-
sults will be broken down by HCP characteristics (e.g.,
sex, discipline) to perform sub-group analysis. Sensitivity
analyses will be performed on studies that are deemed
“low risk of bias.”
If studies are identified that evaluate the effect of an
intervention to change HCP adherence to recommenda-
tions in CPGs for the prescription of opioid medication,
relevant statistics (e.g., F-values, means and SDs) will be
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used to calculate standardized mean differences using for-
mulae described previously [76]. A meta-analysis will be
performed if ≥ 3 studies are identified that evaluate a the-
oretically and methodologically similar intervention [77].
Analytic computations will be performed using Compre-
hensive Meta-Analysis software (CMA; [78]). Evidence for
publication bias will be assessed through visual inspection
of a funnel plot, and fail-safe Ns will be calculated using
Orwin’s formula [79] with the recommended criterion of
effect size of 0.20.
Assessing confidence in evidence
As per recommendations [74], the Grades of Recom-
mendation, Assessment, Development, and Evaluation-
Confidence in the Evidence from Qualitative Reviews
(GRADE-CERQual) approach [80] will be used to
assess confidence in synthesized qualitative results. The
CERQual approach includes four components: (1)
methodological limitations of individual studies, (2)
relevance of the review question of individual studies,
(3) coherence of review results, and (4) adequacy of
data supporting a review result. Confidence in quantita-
tive evidence will be evaluated using the GRADE
approach [81].
Discussion
This will be the first knowledge synthesis to elucidate
the factors associated with clinical inertia with respect to
HCP guideline adherence for the safe prescription of
opioid medication for the management of chronic
non-cancer pain. The knowledge generated by this syn-
thesis is vital for better understanding the concerns that
HCPs have about prescribing opioid medications. Such
knowledge will be used to elucidate theory-driven and
evidence-based behavior change principles that specific-
ally target the various facets of clinical inertia identified.
Identified behavior change principles can be integrated
into existing interventions that have proven effective
(e.g., education) or used to develop novel interventions
(e.g., education delivered using motivational communi-
cation—a broad set of evidence-based, patient-centered
techniques designed to promote motivation for behavior
change [82]). The ultimate goal of this work is to
optimize opioid prescribing practices in order to prevent
opioid-related morbidity and mortality without restrict-
ing a HCP’s ability to select the most appropriate treat-
ment for an individual patient.
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